Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LBT-3627 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Healthy Volunteers - SAD | EXPERIMENTAL | Single dose of LBT-3627 administered to healthy volunteers |
| Parkinson's disease patients - SAD | EXPERIMENTAL | Single dose of LBT-3627 administered to Parkinson's disease patients |
| Parkinson's disease patients - MAD | EXPERIMENTAL | Multiple doses of LBT-3627 administered to Parkinson's disease patients |
| Name | Type | Description |
|---|---|---|
| LBT-3627 | DRUG | Synthetic peptide |
| Placebo | DRUG | Vehicle |
Both cohorts (Healthy Volunteers and Parkinson's Disease) Key inclusion criteria * Male or female, 30-89 years inclusive at screening * BMI 18-32 kg/m² * Vital signs, ECG (QTcF \<450 ms male / \<470 ms female), and safety labs without clinically significant abnormality; no orthostatic hypotension ...